AKRO Akero Therapeutics

Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Akero Therapeutics to Present at the Jefferies Virtual Healthcare Conference

SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. (ET).

About Akero Therapeutics

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial in NASH patients with F2/F3 fibrosis, the HARMONY study. Akero is headquartered in South San Francisco. Visit  for more information.

Investor Contact:

Christina Tartaglia

212.362.1200

Media Contact:

650.487.6488



EN
28/05/2021

Underlying

AKROAkero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akero Therapeutics

 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billi...

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share  Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (“Akero”) (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has entered into a definitive agreement to be acquired by Novo Nordisk A...

October 9, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and ...

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025 SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 taking place Novem...

October 7, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global...

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025, at 10:45 a.m. E.T. in New York, NY. A live webcast of the Company presentation will be available through the invest...

August 28, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMON...

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced publicatio...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AKRO Akero Therapeut...

Akero Therapeutics Reports Second Quarter 2025 Financial Results and P...

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and corroborating the anti-fibrotic activity of EFX seen in patients with pre-cirrhotic (F2-F3) MASH Cash, cash equivalents and short and long-term marketable securities of $1,086.2 million at June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. ...

August 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch